GSK, ChemoCentryx ink $1.5B pact
DEALS |
|||
WHO |
WITH |
WHAT |
SCOOP |
GlaxoSmithKline |
ChemoCentryx |
$1.5B collaboration pact |
The deal revolves around developing new therapies from chemokine and chemoattractant receptors for inflammatory diseases. |
Mylan Laboratories |
Matrix Laboratories |
$735 million acquisition |
In a move to expand its reach around the globe, Mylan Laboratories has acquired a majority interest in India's Matrix Laboratories. |
Infinity Pharmaceuticals |
MedImmune |
$500M development deal |
Infinity Pharmaceuticals and MedImmune will advance new therapies for blood-related cancers and solid tumors. |
Dishman Pharmaceuticals and Chemicals |
Carbogen Amcis |
$75M purchase |
Carbogen Amcis controls three production facilities. Dishman says it expects to be able to improve margins at the contract manufacturing operation. |
Dyax |
Paul Capital Partners |
$30M payment |
Dyax receives the payment from Paul Capital Partners in exchange for a portion of the revenue generated by its Phage Display Licensing and Funded Research Program. |
Isolagen |
Agera Laboratories |
$2.67M deal |
Agera Laboratories makes clinically developed skincare products. |
Orthodontix |
Protalix |
Merger |
Once the merger is complete a small group of investors will invest $15 million in Protalix in exchange for 14 percent of the company. |